WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016060517) COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/060517    International Application No.:    PCT/KR2015/010976
Publication Date: 21.04.2016 International Filing Date: 16.10.2015
IPC:
A61K 31/357 (2006.01), A61K 31/192 (2006.01), A61P 3/04 (2006.01), A61P 3/10 (2006.01)
Applicants: HYUNDAI PHARM CO., LTD. [KR/KR]; 55, Jandari-gil Pungse-myeon, Dongnam-gu Cheonan-si, Chungcheongnam-do 31213 (KR)
Inventors: YANG, Jin; (KR).
KIM, Jin Woong; (KR).
LEE, Han Kyu; (KR).
KIM, Jae Hyun; (KR).
SON, Chang Mo; (KR).
LEE, Kyu Hwan; (KR).
CHOI, Hyung-Ho; (KR).
KIM, Daehoon; (KR).
HA, Tae-Young; (KR).
RHEE, Jaekeol; (KR)
Agent: YANG, Boo Hyun; Suite 301 Chungdong Building, 1922 Nambusunhwan-ro, Gwanak-gu Seoul 08793 (KR)
Priority Data:
10-2014-0141216 17.10.2014 KR
Title (EN) COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES
(FR) PRÉPARATION COMPOSITE, CONTENANT UN NOUVEAU DÉRIVÉ DE L'ACIDE 3-(4- (BENZYLOXY)PHÉNYL)HEX-4-INOÏQUE ET UN AUTRE PRINCIPE ACTIF, ET DESTINÉE À PRÉVENIR OU TRAITER LES MALADIES MÉTABOLIQUES
(KO) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.
(FR)La présente invention concerne une composition pharmaceutique destinée à prévenir ou traiter les maladies métaboliques, dans laquelle un nouveau dérivé de l'acide 3-(4-(benzyloxy)phényl)hex-4-inoïque et au moins un autre principe actif, qui est choisi dans le groupe constitué des médicaments à base d'inhibiteurs de la dipeptidyl-peptidase-4 (DPPIV), de sulfonylurée, de thiazolidinedione (TZD), de biguanide et d'inhibiteurs du co-transporteur de sodium/glucose de type 2 (SGLT2), peuvent être administrés en combinaison ou sous la forme d'une préparation composite. L'utilisation de la composition de la présente invention peut produire un effet remarquable en matière de réduction de la glycémie sanguine chez divers modèles animaux du diabète, et la composition de la présente invention peut être avantageusement utilisée en tant que composition pharmaceutique pour prévenir ou traiter les maladies métaboliques, telles que l'obésité, le diabète de type I, le diabète de type II, les symptômes de l'intolérance au glucose, les symptômes de la résistance à l'insuline, l'hyperglycémie, l'hyperlipidémie, l'hypertriglycéridémie, l'hypercholestérolémie, la dyslipidémie et le syndrome X.
(KO)본 발명은 신규한 3-(4-(벤질옥시)페닐)핵스-4-이노익 산 유도체와 디펩티딜펩티드 IV(Dipeptidyl pept idas e-4, DPPIV) 억제제 계열, 설포닐 우레아(Sulfonylurea) 계열, 치아졸리딘디온 (Thiazolidinediones, TZD) 계 열, 바이구아니드(Biguanide) 계열 및 SGLT2(sodium/glucose cotransporter 2) 억제제 계열 약물로 이루어지는 군으로부터 적어도 하나 이상의 다른 유 효성분을 선택하여 병용 또는 복합제 형태로 투여할 수 있는 대사성 질환 에 대한 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명의 조성 물을 이용함으로써, 다양한 동물 당뇨 질환 모델에서 현저히 우수한 혈당강 하효과를 얻을 수 있고, 비만, I형 당뇨병, II형 당뇨병, 내당증, 인슐린 내성증, 고혈당증, 고지질혈증, 고중성지방혈증, 고콜레스테롤혈증, 이상지 질혈증, X 증후군 등의 대사성 질환에 대한 예방 또는 치료용 약학적 조성 물로 유용하게 사용할 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)